drugset / Trial / NCT01504256
Catumaxomab for Treatment of Peritoneal Carcinomatosis in Patients With Gastric Adenocarcinomas
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy of catumaxomab by determination of the rate of macroscopic complete remissions of peritoneal carcinomatosis after treatment with one cycle (four doses) of catumaxomab followed by six cycles of routine neoadjuvant chemotherapy.
Timeline
- Start
- 2011-10
- Primary completion
- 2017-03
- Completion
- 2017-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catumaxomab | Monoclonal antibody | 150 ug | Other |
| Background | Docetaxel | Small molecule | 50 mg/m2 | — |
| Background | Leucovorin | Small molecule | 200 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2600 mg/m2 | — |